Sunburst Financial Group LLC Sells 130 Shares of Amgen Inc. (NASDAQ:AMGN)

Sunburst Financial Group LLC trimmed its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 5.3% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,304 shares of the medical research company’s stock after selling 130 shares during the quarter. Sunburst Financial Group LLC’s holdings in Amgen were worth $652,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of AMGN. BOK Financial Private Wealth Inc. purchased a new stake in Amgen in the fourth quarter valued at approximately $29,000. United Community Bank purchased a new position in Amgen during the fourth quarter worth approximately $29,000. Planned Solutions Inc. acquired a new position in shares of Amgen during the 4th quarter worth approximately $30,000. Delos Wealth Advisors LLC lifted its position in shares of Amgen by 2,500.0% during the 4th quarter. Delos Wealth Advisors LLC now owns 104 shares of the medical research company’s stock valued at $30,000 after buying an additional 100 shares in the last quarter. Finally, Hartford Financial Management Inc. grew its stake in Amgen by 56.9% in the 4th quarter. Hartford Financial Management Inc. now owns 113 shares of the medical research company’s stock valued at $33,000 after acquiring an additional 41 shares during the period. Institutional investors own 76.50% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have issued reports on AMGN shares. BMO Capital Markets increased their price objective on shares of Amgen from $336.00 to $355.00 and gave the company an “outperform” rating in a report on Friday, May 3rd. Barclays upgraded Amgen from an “underweight” rating to an “equal weight” rating and raised their target price for the company from $230.00 to $300.00 in a research report on Friday, May 3rd. William Blair upgraded Amgen from a “market perform” rating to an “outperform” rating in a report on Friday, May 3rd. Royal Bank of Canada upped their price objective on shares of Amgen from $328.00 to $332.00 and gave the company an “outperform” rating in a research note on Friday, June 14th. Finally, UBS Group boosted their price objective on Amgen from $284.00 to $307.00 and gave the stock a “neutral” rating in a research note on Friday, May 3rd. Ten equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $307.35.

Amgen Trading Up 0.0 %

NASDAQ AMGN traded up $0.14 during trading on Friday, hitting $313.83. The stock had a trading volume of 365,459 shares, compared to its average volume of 2,765,879. The company has a quick ratio of 0.98, a current ratio of 1.42 and a debt-to-equity ratio of 11.96. The company has a market capitalization of $168.35 billion, a PE ratio of 44.81, a PEG ratio of 2.83 and a beta of 0.60. The firm has a 50 day moving average price of $299.67 and a 200 day moving average price of $291.67. Amgen Inc. has a twelve month low of $218.44 and a twelve month high of $329.72.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Thursday, May 2nd. The medical research company reported $3.96 earnings per share for the quarter, beating analysts’ consensus estimates of $3.76 by $0.20. Amgen had a net margin of 12.74% and a return on equity of 156.21%. The firm had revenue of $7.45 billion during the quarter, compared to analysts’ expectations of $7.45 billion. During the same quarter in the previous year, the business posted $3.98 earnings per share. The business’s quarterly revenue was up 22.0% compared to the same quarter last year. As a group, equities research analysts forecast that Amgen Inc. will post 19.47 earnings per share for the current year.

Insider Buying and Selling

In related news, SVP Nancy A. Grygiel sold 2,117 shares of the company’s stock in a transaction that occurred on Friday, May 3rd. The shares were sold at an average price of $313.09, for a total transaction of $662,811.53. Following the sale, the senior vice president now directly owns 9,883 shares in the company, valued at $3,094,268.47. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 0.69% of the stock is currently owned by insiders.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.